Ignite Creation Date:
2024-05-05 @ 12:06 PM
Last Modification Date:
2024-10-26 @ 9:20 AM
Study NCT ID:
NCT00243204
Status:
TERMINATED
Last Update Posted:
2007-06-08
First Post:
2005-10-19
Brief Title:
Study of Talabostat Docetaxel Versus Docetaxel in Stage IIIBIV Non-Small Cell Lung Cancer NSCLC After Failure of Platinum-Based Chemotherapy
Sponsor:
Organization:
Point Therapeutics
Study Design
Study Type:
INTERVENTIONAL
Expanded Access Type Individual:
None
Expanded Access Type Intermediate:
None
Expanded Access Type Treatment:
None
Patient Registry:
None
Target Duration:
None
Design Allocation:
Design Intervention Model:
Design Intervention Model Description:
Design Masking Description:
Bio Spec Retention:
None
Bio Spec Description:
None
Enrollment Count:
400
Enrollment Type:
ESTIMATED
Design Primary Purpose:
Design Masking:
Phases:
| Name |
|---|
| PHASE3 |
Observational Models:
Time Perspective List:
Who Masked List: